Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.43 |
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | HTR6 | P50406 | 7/20 | 0.43 |
| ▸ | HTR7 | P34969 | 6/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633493 | 0.84 | DRD2 (0.41) | DRD2HTR1AHTR6HTR7HTR2A | |
| SCHEMBL14232129 | 0.82 | DRD2 (0.41) | DRD2HTR1AHTR6HTR7HTR2A | |
| SCHEMBL13633485 | 0.81 | DRD2 (0.47) | DRD2HTR1AHTR6HTR7HTR2A | |
| SCHEMBL13633465 | 0.81 | HTR1A (0.51) | DRD2HTR1AHTR7HTR2ADRD1 | |
| SCHEMBL13633434 | 0.77 | DRD2 (0.52) | DRD2HTR1AHTR7HTR2ADRD1 | |
| SCHEMBL13633492 | 0.75 | DRD2 (0.45) | DRD2HTR1AHTR7HTR2ADRD1 | |
| SCHEMBL13633482 | 0.75 | HTR1A (0.54) | DRD2HTR1AHTR7HTR2ADRD1 | |
| SCHEMBL13633481 | 0.74 | DRD2 (0.48) | DRD2HTR1AHTR7HTR2ADRD1 | |
| SCHEMBL13633483 | 0.74 | LTA4H (0.53) | DRD2HTR1AHTR7HTR2ADRD1 | |
| SCHEMBL1444314 | 0.69 | HPGD (0.59) | FAAHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2009-11-12 | — | — | US | disclosed |
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2009-11-12 | — | — | US | disclosed |
| WO-2007135131-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | DRD2 37/4885HTR1A 130/4885HTR6 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.